



The 22nd JFCR-ISCC New Antitumor Agents under Development in the US, Europe and Japan

2017 December 13 (Wed) 13:00 -19:00
December 14 (Thu) 9:00 -18:30

Miraikan

National Museum of Emerging Science and Innovation
2-3-6, Aomi, Koto-ku, Tokyo, Japan

Dec. 13 (Wed)

Session 1

13:10 -

Genetic biomarkers and rational combinations for cancer immunotherapy

Scott K. Pruitt *Merck Research Laboratories*

The first tumor-type agnostic regulatory approval: Pembrolizumab for the treatment of advanced MSI-H/dMMR cancer

Philip J. Stephens *Foundation Medicine*

Identification of novel modulators of response to immune checkpoint blockade in lung cancer patients through the marrying of clinical and genomic data

Session 2

15:00 -

Sophisticated DNA damage inducers for cancer therapy

Yves G. Pommier *NCI, NIH*

PARP trapping and replicative damages

Hiroki Nagase *Chiba Cancer Ctr. Res. Inst.*

Targeting the Achilles' heel of cancer: Sequence specific alkylation at KRAS driver gene DNA mutations

16:20 -

Poster Flash Talks

17:20 -

Poster Session & Mixer

Dec. 14 (Thu)

Session 3

9:00 -

New technologies and drugs under clinical or preclinical investigations

Pablo Umaña *Roche Glycart AG*

CEA-TCB: A novel bispecific antibody targeting solid tumors

Antoine Yver *Daiichi-Sankyo*

Clinical study results of DS-8201a, a novel HER2-targeting ADC with a DNA topoisomerase I inhibitor

Lothar Finke *Incyte Biosciences Japan*

Targeting IDO1 in the TME: A novel approach to combination immunotherapy for cancer

11:30 -

Poster Discussion Session

12:20 -

Luncheon Seminar

Thomas Metz *Charles River Discovery Research Services GmbH*

Preclinical in vivo profiling of i/o and non i/o anti-cancer agents: Optimization of model selection

Session 4

13:30 -

Drug discovery and preclinical evaluation using cellular and patient-derived models

Supported by MEXT Grant-in-Aid for Scientific Research on Innovative Areas "Integrated Analysis and Regulation of Cellular Diversity (4904)"

Andrew Schile *Jackson Laboratory*

"Onco-Hu" mouse model for evaluating immuno-oncology therapeutics

Masahiro Inoue *Osaka Int. Cancer Inst.*

Drug screening by use of a panel of primary cultured cancer spheroids derived from clinical tumor samples

14:50 -

Special Lecture

Bruce A. Chabner *MGH / Harvard Med. Sch.*

Challenges and opportunities for targeted therapies

Session 5

16:20 -

Next generation of combination cancer immunotherapy

Supported by  Bristol-Myers Squibb

Jean Viallet *BMS*

Overview of IO drug development

Michael Axelson *BMS*

Towards principles of combination therapy in IO: Example of anti-LAG3

Hiroyoshi Nishikawa *Res. Inst., EPOC, NCCI Nagoya Univ.*

Genome-immune analyses to decipher anti-tumor immune responses

Contact : Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
jfc-r-iscc@ml.jfcr.or.jp

<http://iscc.umin.jp/>

The 22nd JFCR-ISCC is supported by following companies: Bristol-Myers Squibb K.K., Kyowa Hakko Kirin Co., Ltd., Taiho Pharmaceutical Co., Ltd., AbbVie Inc., Biogen Japan Ltd., Celgene K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., FUJIFILM Corporation, Meiji Seika Pharma Co., Ltd., MSD K.K., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Sysmex Corporation, Yakult Honsha Co., Ltd., Zenyaku Kogyo Co., Ltd., and Otsuka Pharmaceutical Co., Ltd.